In a randomized controlled trial, Corren et al. found that dupilumab 200/300 mg every two weeks reduced severe asthma exacerbation rates (-36.9%/-45.5%; both p < 0.01) and improved FEV1 at week 12 in LIBERTY ASTHMA QUEST patients with or without allergic asthma (total serum IgE ≥30 IU/mL and ≥1 perennial aeroallergen-specific IgE ≥0.35 kU/L). The gene discussed is IGHE; the disease is allergic asthma.